"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Descriptor ID |
D008103
|
| MeSH Number(s) |
C06.552.630
|
| Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 3 | 2 | 5 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 6 | 3 | 9 |
| 2005 | 6 | 1 | 7 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 4 | 2 | 6 |
| 2009 | 4 | 2 | 6 |
| 2010 | 8 | 3 | 11 |
| 2011 | 11 | 7 | 18 |
| 2012 | 12 | 3 | 15 |
| 2013 | 14 | 0 | 14 |
| 2014 | 14 | 2 | 16 |
| 2015 | 13 | 7 | 20 |
| 2016 | 21 | 6 | 27 |
| 2017 | 20 | 8 | 28 |
| 2018 | 17 | 10 | 27 |
| 2019 | 21 | 5 | 26 |
| 2020 | 24 | 13 | 37 |
| 2021 | 13 | 25 | 38 |
| 2022 | 5 | 31 | 36 |
| 2023 | 5 | 42 | 47 |
| 2024 | 25 | 8 | 33 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
-
Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: a multicenter randomized clinical trial. J Natl Cancer Inst. 2025 Feb 01; 117(2):262-269.
-
Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice. Am J Pathol. 2025 Mar; 195(3):542-560.
-
Access to Evaluation for Liver Transplantation in the Veterans Health Administration. Dig Dis Sci. 2025 Feb; 70(2):552-565.
-
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial. Gut. 2024 Nov 11; 73(12):2037-2044.
-
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
-
National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11).
-
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
-
Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease. J Pediatr Gastroenterol Nutr. 2024 Dec; 79(6):1192-1198.